| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry
Lexaria's technology could enhance performance and lower side effects
KELOWNA, BC / ACCESS Newswire / April 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") strategic update following important industry developments reported both by Pfizer® Inc. and by Eli Lilly and Company®.
Nearly all of the world's top pharmaceutical companies are racing to develop new oral GLP-1 drugs, including: Amgen®, AstraZenca, Eli Lilly, Merck®, Novo Nordisk®, Pfizer®, and Roche®.
By enhancing the performance of oral dosing choices as a replacement for disliked injections; and by reducing adverse events - often the #1 reason that patients stop using GLP-1 drugs - Lexaria's proprietary DehydraTECH technology could be of vital importance to any of these companies in their pursuit of the next oral GLP-1 drug(s).
